Pages that link to "Q29547347"
Jump to navigation
Jump to search
The following pages link to Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target (Q29547347):
Displayed 50 items.
- HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response (Q21090490) (← links)
- Few and far between: how HIV may be evading antibody avidity (Q21090507) (← links)
- Structural mechanism of trimeric HIV-1 envelope glycoprotein activation (Q21131394) (← links)
- bNAber: database of broadly neutralizing HIV antibodies (Q24567758) (← links)
- A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union (Q24568048) (← links)
- Increasing the potency and breadth of an HIV antibody by using structure-based rational design (Q24631510) (← links)
- Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals (Q24635002) (← links)
- Immunoregulatory functions of immune complexes in vaccine and therapy (Q26738396) (← links)
- The Significance of a Common Idiotype (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C Virus (Q26767258) (← links)
- Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines - A review from a regulatory perspective (Q26770839) (← links)
- Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection (Q26775082) (← links)
- Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1 (Q26782237) (← links)
- The HIV glycan shield as a target for broadly neutralizing antibodies (Q26786540) (← links)
- Recent strategies targeting HIV glycans in vaccine design (Q26823603) (← links)
- Structural insights on the role of antibodies in HIV-1 vaccine and therapy (Q26829461) (← links)
- A Blueprint for HIV Vaccine Discovery (Q26829865) (← links)
- A brief history of the global effort to develop a preventive HIV vaccine (Q26851165) (← links)
- A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes (Q26860116) (← links)
- Nonhuman primate models for HIV/AIDS vaccine development (Q26861148) (← links)
- Designing synthetic vaccines for HIV (Q26862617) (← links)
- Antibody responses to envelope glycoproteins in HIV-1 infection (Q26991572) (← links)
- HIV-1 neutralizing antibodies: understanding nature's pathways (Q27000480) (← links)
- The Antibody Response against HIV-1 (Q27000889) (← links)
- The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise (Q27010375) (← links)
- Antibodies in HIV-1 vaccine development and therapy (Q27011574) (← links)
- HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design (Q27022055) (← links)
- A global approach to HIV-1 vaccine development (Q27024614) (← links)
- Virological features associated with the development of broadly neutralizing antibodies to HIV-1 (Q27025177) (← links)
- HIV broadly neutralizing antibody targets (Q27026662) (← links)
- Catching HIV 'in the act' with 3D electron microscopy (Q27026806) (← links)
- Glycotherapy: new advances inspire a reemergence of glycans in medicine (Q27027997) (← links)
- A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen (Q27302081) (← links)
- Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants (Q27304735) (← links)
- A saposin-lipoprotein nanoparticle system for membrane proteins. (Q27313390) (← links)
- Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site (Q27319450) (← links)
- Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells (Q27320687) (← links)
- Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 (Q27322403) (← links)
- Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa (Q27322437) (← links)
- HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization (Q27324184) (← links)
- An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV (Q27349203) (← links)
- HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV (Q27497560) (← links)
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 (Q27644478) (← links)
- Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus (Q27644501) (← links)
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies (Q27644515) (← links)
- Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design (Q27644634) (← links)
- Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity (Q27654848) (← links)
- Interactions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing Activity (Q27658138) (← links)
- Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction (Q27661588) (← links)
- Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 (Q27662155) (← links)
- Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 (Q27662167) (← links)